This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kimberlin, D. W.
Right arrow Articles by Whitley, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kimberlin, D. W.
Right arrow Articles by Whitley, R. J.
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 108 No. 2 August 2001, pp. 230-238

Safety and Efficacy of High-Dose Intravenous Acyclovir in the Management of Neonatal Herpes Simplex Virus Infections

Received Sep 1, 2000; accepted Dec 11, 2000.

David W. Kimberlin*, Chin-Yu Lin*, Richard F. JacobsDagger , Dwight A. Powell§, Lawrence Coreyparallel , William C. Gruber, Mobeen Rathore#, John S. Bradley**, Pamela S. DiazDagger Dagger , Mary Kumar§§, Ann M. Arvin||, Kathleen Gutierrez||, Mark Shelton¶¶, Leonard B. Weiner##, John W. Sleasman***, Teresa Murguía de SierraDagger Dagger Dagger , Stephen Weller§§§, Seng-Jaw Soong*, Jan Kiell*, Fred D. Lakeman*, Richard J. Whitley*, and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Groupa

From the * Department of Pediatrics, University of Alabama at Birmingham, Alabama; Dagger  Department of Pediatrics, University of Arkansas, Little Rock, Arkansas; § Department of Pediatrics, Ohio State University, Columbus, Ohio; parallel  Department of Medicine, University of Washington, Seattle, Washington;  Department of Pediatrics, Vanderbilt University, Nashville, Tennessee; # Department of Pediatrics, University of Florida Health Science Center, Jacksonville, Florida; ** Department of Pediatrics, University of California San Diego, California; Dagger Dagger  Chicago Department of Public Health, Chicago, Illinois; §§ Department of Pediatrics, Case Western Reserve, Cleveland, Ohio;|| Department of Pediatrics, Stanford University, Stanford, California; ¶¶ Cook Children's Medical Center, Fort Worth, Texas; ## Department of Medicine, State University of New York, Syracuse, New York; *** Department of Pediatrics, University of Florida, Gainesville, Florida; Dagger Dagger Dagger  Hospital Infantil de Mexico, Mexico City, Mexico; and §§§ Glaxo Wellcome Inc, Research Triangle Park, North Carolina.

Objective.  The objective of this investigation was to establish the safety of high-dose (HD) acyclovir for the treatment of neonatal herpes simplex virus (HSV) disease. In addition, an estimate of therapeutic efficacy was sought, both with respect to mortality and to morbidity. Virologic efficacy of HD acyclovir was also assessed.

Participants.  Infants who were <= 28 days old and whose disease was considered to be caused by HSV were enrolled in this study. Patients with central nervous system (CNS; N = 28) or disseminated (N = 41) HSV infection were offered participation in the trial. A small number of patients with HSV disease limited to the skin, eyes, or mouth (SEM; N = 10) or whose disease was clinically consistent with HSV but who did not have virologic confirmation of infection (N = 9) also were enrolled on a compassionate basis. Only patients with virologically confirmed HSV disease were included in efficacy analyses. All enrolled patients were included in safety analyses.

Methods.  The study was an open-label evaluation of intravenous acyclovir at dosages higher than the 30 mg/kg/d standard dosage approved by the US Food and Drug Administration. The first 16 patients enrolled received intermediate-dose (ID) acyclovir (45 mg/kg/d), and the next 72 patients received HD acyclovir (60 mg/kg/d). Acyclovir was administered in 3 divided daily doses for 21 days. Neonates were assessed prospectively throughout treatment and at scheduled follow-up visits for the first 4 years of life. Data were compared with those of a previous National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group trial in which patients received standard-dose (SD) acyclovir for 10 days and in which identical methods (with the exception of acyclovir dosage and duration of therapy) were used.

Results.  Six (21%) of 29 HD acyclovir recipients whose HSV disease remained localized to the SEM or CNS experienced neutropenia. One of the 6 had an absolute neutrophil count <500/mm3, and 5 patients had an absolute neutrophil count (ANC) between 500/mm3 and 1000/mm3. In all 6 cases, the ANC recovered during continuation of acyclovir at the same dosage or after completion of acyclovir therapy, and there were no apparent adverse sequelae of the transient neutropenia. No other drug-related adverse events were reported among ID or HD recipients, and no other laboratory aberrations could be correlated specifically with antiviral therapy. The survival rate for the patients with disseminated HSV disease treated with HD acyclovir was significantly higher than for those in the previous study treated with SD acyclovir, with an odds ratio (OR) of 3.3 (95% confidence interval [CI]: 1.4-7.9). For patients with CNS disease, however, survival rates were similar for the HD and SD groups. To assess the effect of HD acyclovir on survival for the entire population with neonatal HSV disease, the Cox proportional hazards regression analysis was performed with stratification for disease category (CNS versus disseminated). In performing this analysis, differences in mortality for each disease category were weighted to allow statistical comparison of the treatment dosage groups (HD, ID, and SD). This analysis indicated that the survival rate for patients treated with HD acyclovir was statistically significantly higher than for patients treated with SD acyclovir (OR: 3.3; 95% CI: 1.5-7.3). Recipients of HD acyclovir had a borderline significant decrease in morbidity compared with SD recipients, after stratification for the extent of disease (SEM vs CNS vs disseminated) and controlling for the potential confounding factors of HSV type (HSV-1 vs. HSV-2), prematurity, and disease severity (seizures). Patients treated with HD acyclovir were 6.6 times (adjusted OR; 95% CI: 0.8-113.6) as likely to be developmentally normal at 12 months of age as patients treated with SD therapy.

Conclusion.  These data support the use of a 21-day course of HD (60 mg/kg/d) intravenous acyclovir to treat neonatal CNS and disseminated HSV disease. Throughout the course of HD acyclovir therapy, serial ANC determination should be made at least twice weekly. Decreasing the acyclovir dosage or administering granulocyte colony-stimulating factor should be considered if the ANC remains below 500/mm3 for a prolonged period.  Key words:  newborn, herpes simplex virus, acyclovir.




This article has been cited by other articles:


Home page
 Arch Pediatr Adolesc MedHome page
A. C. Caviness, G. J. Demmler, J. M. Swint, and S. B. Cantor
Cost-effectiveness Analysis of Herpes Simplex Virus Testing and Treatment Strategies in Febrile Neonates
Arch Pediatr Adolesc Med, July 1, 2008; 162(7): 665 - 674.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. M. Avram, V. Gobel, and A. Sepehr
Case 30-2007 -- A Newborn Girl with Skin Lesions
N. Engl. J. Med., September 27, 2007; 357(13): 1327 - 1335.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
M. T. Orr, N. N. Orgun, C. B. Wilson, and S. S. Way
Cutting Edge: Recombinant Listeria monocytogenes Expressing a Single Immune-Dominant Peptide Confers Protective Immunity to Herpes Simplex Virus-1 Infection
J. Immunol., April 15, 2007; 178(8): 4731 - 4735.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
L. R. Stanberry
Neonatal Herpes in Premature Infants: A Special Problem
Pediatrics, December 1, 2006; 118(6): 2543 - 2544.
[Full Text] [PDF]

Home page
 PediatricsHome page
D. P. O'Riordan, W. C. Golden, and S. W. Aucott
Herpes Simplex Virus Infections in Preterm Infants
Pediatrics, December 1, 2006; 118(6): e1612 - e1620.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
A. T. N. Tita, W. A. Grobman, and D. J. Rouse
Antenatal herpes serologic screening: an appraisal of the evidence.
Obstet. Gynecol., November 1, 2006; 108(5): 1247 - 1253.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
J. S. Sheffield, J. B. Hill, L. M. Hollier, V. R. Laibl, S. W. Roberts, P. J. Sanchez, and G. D. Wendel Jr
Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial.
Obstet. Gynecol., July 1, 2006; 108(1): 141 - 147.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
R. Y. Kropp, T. Wong, L. Cormier, A. Ringrose, S. Burton, J. E. Embree, and M. Steben
Neonatal herpes simplex virus infections in Canada: results of a 3-year national prospective study.
Pediatrics, June 1, 2006; 117(6): 1955 - 1962.
[Abstract] [Full Text] [PDF]

Home page
 Obstet GynecolHome page
Z. A. Brown, C. Gardella, A. Wald, R. A. Morrow, and L. Corey
Genital Herpes Complicating Pregnancy
Obstet. Gynecol., October 1, 2005; 106(4): 845 - 856.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
L. M. Frenkel
Challenges in the Diagnosis and Management of Neonatal Herpes Simplex Virus Encephalitis
Pediatrics, March 1, 2005; 115(3): 795 - 797.
[Full Text] [PDF]

Home page
 PediatricsHome page
M. Fonseca-Aten, A. F. Messina, H. S. Jafri, and P. J. Sanchez
Herpes Simplex Virus Encephalitis During Suppressive Therapy With Acyclovir in a Premature Infant
Pediatrics, March 1, 2005; 115(3): 804 - 809.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. W. Kimberlin and D. J. Rouse
Genital Herpes
N. Engl. J. Med., May 6, 2004; 350(19): 1970 - 1977.
[Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
D. W. Kimberlin
Neonatal Herpes Simplex Infection
Clin. Microbiol. Rev., January 1, 2004; 17(1): 1 - 13.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
H Kimura, M Futamura, Y Ito, Y Ando, S Hara, H Sobajima, Y Nishiyama, and T Morishima
Relapse of neonatal herpes simplex virus infection
Arch. Dis. Child. Fetal Neonatal Ed., November 1, 2003; 88(6): F483 - 486.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
Z. A. Brown, A. Wald, and L. Corey
Cesarean Delivery and Risk of Herpes Simplex Virus Infection--Reply
JAMA, May 7, 2003; 289(17): 2208 - 2209.
[Full Text] [PDF]

Home page
 JAMAHome page
Z. A. Brown, A. Wald, R. A. Morrow, S. Selke, J. Zeh, and L. Corey
Effect of Serologic Status and Cesarean Delivery on Transmission Rates of Herpes Simplex Virus From Mother to Infant
JAMA, January 8, 2003; 289(2): 203 - 209.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. W. Kimberlin, C.-Y. Lin, R. F. Jacobs, D. A. Powell, L. M. Frenkel, W. C. Gruber, M. Rathore, J. S. Bradley, P. S. Diaz, M. Kumar, et al.
Natural History of Neonatal Herpes Simplex Virus Infections in the Acyclovir Era
Pediatrics, August 1, 2001; 108(2): 223 - 229.
[Abstract] [Full Text] [PDF]